From Bloomberg:
Pfizer Inc., the world's biggest drugmaker, won a U.S. committee's support for the first inhaled insulin as an alternative to needles for 4 million American diabetics.
A panel of doctors and statisticians voted 7-2 today to advise the Food and Drug Administration to clear Exubera, developed by Nektar Therapeutics, Pfizer and Sanofi-Aventis SA, for use in people with both juvenile and adult-onset diabetes. The agency usually follows the advice of its committees. ...more
(Editor's Note: I have not found anything regarding news of a Canadian drug application for Exubera.)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment